New Day Diagnostics LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 21, 2027The maintenance fee for Methods and Nucleic Acids for Determining the Prognosis of a Cancer Subject (US 10,626,462) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,385,402 | Methods and nucleic acids for analyses of cellular proliferative disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 7,749,702 | Methods and nucleic acids for the analyses of cellular proliferative disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 7,951,563 | Methods and nucleic acids for analysis of cellular proliferative disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,605,306 | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 8,912,129 | Method for the determination of the DNA methylation level of a CPG position in identical cells within a tissue sample In force · High confidence | In force | High confidence | |
| US 10,731,215 | Method for determining the presence or absence of methylation in a sample In force · From the USPTO record | In force | From the USPTO record | |
| US 12,110,558 | Methods and Nucleic Acids for Determining the Prognosis of a Cancer Subject In force · Low confidence | In force | Low confidence | |
| US 10,626,462 | Methods and Nucleic Acids for Determining the Prognosis of a Cancer Subject In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 12,054,786 | Methods for detecting CpG methylation and for diagnosing cancer In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 9: 14 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending